Brimonidine Tartrate + Timolol MaleateThird Party Manufacturing in India

Brimonidine Tartrate + Timolol Maleate works by employing a dual mechanism to lower intraocular pressure. Brimonidine tartrate acts as a selective alpha-2 adrenergic receptor agonist, reducing aqueous humor production and increasing uveoscleral outflow. Timolol maleate acts as a non-selective beta-adrenergic receptor blocker, decreasing aqueous humor secretion by the ciliary epithelium without affecting pupil size. Unlike monotherapy, this combination provides a synergistic effect, achieving greater pressure reduction than either component used alone. It is highly effective and well-tolerated.

Therapeutic Uses

• Open-Angle Glaucoma: Indicated for reducing intraocular pressure in patients with open-angle glaucoma who are insufficiently controlled on beta-blockers alone.
• Ocular Hypertension: Used to manage elevated intraocular pressure and prevent progressive optic nerve damage.

Why Manufacturers Choose Brimonidine Tartrate + Timolol Maleate

This anti-glaucoma combination has high market priority due to the expanding geriatric demographic requiring chronic ocular maintenance therapy. Utilizing Brimonidine Tartrate + Timolol Maleate third party manufacturing in India ensures a reliable stream of high-margin ophthalmic products. Our production facilities are WHO-GMP certified, utilizing stabilized oxychloro complexes as advanced preservatives to meet contemporary clinical standards and avoid benzalkonium chloride sensitivities.